| Title |
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent PembrolizumabRegional CAR T-Cell Therapy for Mesothelioma
|
|---|---|
| Published in |
Cancer Discovery, July 2021
|
| DOI | 10.1158/2159-8290.cd-21-0407 |
| Pubmed ID | |
| Authors |
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière, Stephen B. Solomon, Valerie W. Rusch, Roisin E. O'Cearbhaill, Amy Zhu, Waseem Cheema, Navin K. Chintala, Elizabeth Halton, John Pineda, Rocio Perez-Johnston, Kay See Tan, Bobby Daly, Jose A. Araujo Filho, Daniel Ngai, Erin McGee, Alain Vincent, Claudia Diamonte, Jennifer L. Sauter, Shanu Modi, Devanjan Sikder, Brigitte Senechal, Xiuyan Wang, William D. Travis, Mithat Gönen, Charles M. Rudin, Renier J. Brentjens, David R. Jones, Michel Sadelain |
X Demographics
The data shown below were collected from the profiles of 54 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 22 | 41% |
| France | 2 | 4% |
| Spain | 2 | 4% |
| Italy | 2 | 4% |
| Brazil | 1 | 2% |
| Canada | 1 | 2% |
| Finland | 1 | 2% |
| Mexico | 1 | 2% |
| United Kingdom | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 19 | 35% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 26 | 48% |
| Scientists | 15 | 28% |
| Practitioners (doctors, other healthcare professionals) | 7 | 13% |
| Science communicators (journalists, bloggers, editors) | 5 | 9% |
| Unknown | 1 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 166 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 166 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 13% |
| Researcher | 20 | 12% |
| Unspecified | 8 | 5% |
| Student > Master | 8 | 5% |
| Other | 6 | 4% |
| Other | 18 | 11% |
| Unknown | 85 | 51% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 13% |
| Biochemistry, Genetics and Molecular Biology | 14 | 8% |
| Immunology and Microbiology | 13 | 8% |
| Unspecified | 8 | 5% |
| Agricultural and Biological Sciences | 5 | 3% |
| Other | 14 | 8% |
| Unknown | 90 | 54% |
Attention Score in Context
This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2023.
All research outputs
#810,031
of 25,726,194 outputs
Outputs from Cancer Discovery
#437
of 4,153 outputs
Outputs of similar age
#20,259
of 448,079 outputs
Outputs of similar age from Cancer Discovery
#18
of 91 outputs
Altmetric has tracked 25,726,194 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,153 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,079 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 91 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.